Insmed Incorporated announced that on June 17, 2021, Christine Pellizzari notified the company that she will retire from her position as the company’s Chief Legal Officer. The company’s Senior Vice President, General Counsel – US, Michael Smith, will be promoted to General Counsel, Senior Vice President. It is expected that Ms. Pellizzari will remain in her role until July 7, 2021, and then continue to provide consulting services thereafter to the company as described in the consulting agreement entered into between Ms. Pellizzari and the Company on June 21, 2021. Following the Retirement Date, Ms. Pellizzari will become a consultant to the Company and be reasonably available to provide consulting services on an as-needed basis to the company, as mutually agreed, until January 15, 2022, subject to extension as set forth in the Consulting Agreement, or as may otherwise be agreed to in writing by Ms. Pellizzari and the company. Michael Smith has been appointed as the company’s General Counsel, Senior Vice President, effective on July 8, 2021. Mr. Smith, age 44, has served as the Company’s Senior Vice President, General Counsel – US since July 2020. Previously, Mr. Smith served as Vice President, Corporate Counsel of the Company from September 2016 to June 2020 and as Corporate Counsel of the Company from April 2014 to August 2016.
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).
INSMED INCORPORATED 
